The answer to the How?
Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.
Pricing
Value determination, value demonstration, value communication
Pricing
It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources for any given drug.
All our services
Value determination
- Value benchmarking / environmental assessments
- Burden of illness studies
- Experience trials
- Economic endpoints in clinical trials
- Outcomes studies: 3B, Phase IV
- Value-based pricing
Value demonstration
- Compliance strategies
- Value analysis, positioning, and message development/testing
- Model construction: burden of illness, cost-benefit, cost-effectiveness
Value communication
- Contracting, negotiation support
- Budget impact model & Training
- Value communications program including publication strategy
- AMCP/NICE and other submissions
- Sales force tools & training value algorithms
Market Access
The ‘perfect market access‘ or the ‘perfect storm’!
European market access challenges usually have acronyms: NICE, HAS, AMNOG, AIFA and CIMP – which give evidence of the global megatrend for rigorous assessments in reimbursement decisions of health technologies (Health Technology Assessment (HTA)).
Pricing
Value determination, demonstration and communication.
It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources.